1999
DOI: 10.1016/s0264-410x(98)00487-3
|View full text |Cite
|
Sign up to set email alerts
|

Recombinant, chimaeric live, attenuated vaccine (ChimeriVax™) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

4
115
0
1

Year Published

2001
2001
2022
2022

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 144 publications
(120 citation statements)
references
References 36 publications
4
115
0
1
Order By: Relevance
“…The mean serum neutralizing antibody titer was 1:39 and is lower than reported for other flaviviruses [9,[18][19][20][21]. Five of six monkeys inoculated with SLE/DEN4 developed viremia with a mean duration of 2.2 days.…”
Section: Replication and Immunogenicity In Rhesus Monkeysmentioning
confidence: 64%
“…The mean serum neutralizing antibody titer was 1:39 and is lower than reported for other flaviviruses [9,[18][19][20][21]. Five of six monkeys inoculated with SLE/DEN4 developed viremia with a mean duration of 2.2 days.…”
Section: Replication and Immunogenicity In Rhesus Monkeysmentioning
confidence: 64%
“…[20][21][22][23]25,26,31 One approach currently being pursued is the construction of antigenic chimeric viruses that possess the nonstructural genes of the attenuated yellow fever vaccine and the structural proteins of one of the four types of dengue virus. 25 Such chimeric viruses bear the genes for prM and E proteins of dengue virus and all other sequences from the yellow fever vaccine virus, including regions that possess some, but not all, of the attenuating mutations of the yellow fever vaccine virus.…”
Section: Discussionmentioning
confidence: 99%
“…24 A similar strategy is also being used to develop attenuated antigenic chimeric dengue virus vaccines based on the attenuation of the yellow fever vaccine virus or the attenuation of the cell-culture passaged dengue viruses. 25,26 The present study examines the level of attenuation for humans of a DEN-4 mutant bearing a 30-nucleotide deletion (⌬30) introduced into its 3Ј-untranslated region by site-directed mutagenesis and that was found previously to be attenuated for rhesus monkeys. 27 Additional studies were carried out to examine whether this ⌬30 mutation present in …”
Section: Introductionmentioning
confidence: 99%
“…8,9 Recombinant DNA technology has greatly facilitated the development of live attenuated vaccines for dengue and other flaviviruses. [10][11][12][13][14][15][16]. The dengue vaccine candidate 2A⌬30 was derived from a cDNA clone of DEN-4 and contains a 30-nucleotide deletion in the 3Ј-untranslated region of the * Equal contribution by the first two authors.…”
Section: Introductionmentioning
confidence: 99%